Jeanne Dople
Family · Oak Ridge, TNNPI 1689037228
Payments from drug & device makers
Across 115 payments — averaging $14.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$437
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$402
- Novartis$187
- GSK$127
- AstraZeneca$94
- Phathom Pharmaceuticals, Inc.$72
- plus $374 from 12 others
What the payments were for
- Food & beverage$1,693100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 39 | $437 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 28 | $402 |
| Novartis | 8 | $187 |
| GSK | 7 | $127 |
| AstraZeneca | 6 | $94 |
| Phathom Pharmaceuticals, Inc. | 5 | $72 |
| Teva Pharmaceuticals USA, Inc. | 3 | $56 |
| Axsome Therapeutics, Inc. | 3 | $50 |
| Novo Nordisk | 3 | $48 |
| Pfizer | 3 | $43 |
| Amgen | 2 | $36 |
| Lilly USA, LLC | 2 | $32 |
| Supernus Pharmaceuticals, Inc. | 1 | $25 |
| Lundbeck LLC | 1 | $20 |
| Mylan Specialty L.p. | 1 | $19 |
| Vertex | 1 | $17 |
| Indivior Inc. | 1 | $15 |
| Gilead | 1 | $13 |
How this compares
$1,693 in reported general payments places this provider in the 70th percentile of 6,706 family providers in Tennessee.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 60 | $69,522 |
| OzempicSemaglutide | 57 | $55,093 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 50 | $23,552 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $16,970 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 23 | $14,516 |
| EliquisApixaban | 18 | $11,420 |
| Spiriva RespimatTiotropium Bromide | 16 | $11,306 |
| JardianceEmpagliflozin | 15 | $10,770 |
| TrulicityDulaglutide | 11 | $10,545 |
| XareltoRivaroxaban | 17 | $9,052 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 95 | $7,107 |
| Ventolin HfaAlbuterol Sulfate | 88 | $5,080 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 147 | $4,909 |
| Gabapentin | 436 | $3,980 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 226 | $2,609 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $32 | $80,06871 claims |
| Novo NordiskOzempic | $48 | $55,09357 claims |
| GSKTrelegy Ellipta | $127 | $16,97027 claims |
| AstraZenecaBreztri Aerosphere | $94 | $14,51623 claims |
| PfizerEliquis | $43 | $11,42018 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 6,706 family providers in Tennessee.
Other family in Oak Ridge
- Brittany AdamsOak Ridge$19K
- Stacy BrownMt Juliet$719K
- Dana WebberKnoxville$499K
- Brandy BiedermanHixson$448K
- Cynthia MillerMurfreesboro$384K
- Tamera ThoenerNashville$254K
- April SwonerHermitage$246K
- Jennifer WilliamsNashville$213K
- Chantil JeffreysGermantown$195K
- Laura PorchCordova$148K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.